



plantformcorp.com

News Release

1920 Yonge Street
Suite 200
Toronto, Ontario
Canada M4S 3E2



October 17, 2012

PlantForm to present at SoCalBio 2012

Investor conference to showcase emerging biotech companies

GUELPH, Ont.—PlantForm Corporation has been invited to present at the 14th annual SoCalBio Investor Conference & Exhibition Nov. 7 in Los Angeles, California.

The event, organized by the Southern California Biomedical Council, will showcase up to 40 emerging biotech, device, diagnostic and informatics companies in the bioscience industry.

PlantForm Corporation is commercializing an ultra-low-cost, plant-based manufacturing platform for monoclonal antibody drugs, protein drugs and vaccines. The company's pipeline features both innovator and biosimilar products, including:

- biosimilar trastuzumab, a plant-produced version of the \$6-billion breast cancer drug Herceptin[®] (market entry anticipated 2015-16)
- biosimilar versions of two additional oncology drugs that have combined annual global sales of \$11.4 billion
- an innovator antibody drug for HIV/AIDS, funded by the Government of Canada and the Bill & Melinda Gates Foundation

The Company recently completed **animal efficacy studies of biosimilar trastuzumab** and is currently raising Series A capital to advance the drug into the regulatory approval process. Projected revenue is more than \$50 million by 2016.

-30-

For more information, please contact:

Don Stewart
President and CEO

don.stewart@plantformcorp.com
(416) 452-7242

Stacey Curry Gunn
Director of Communications

stacey.curry.gunn@plantformcorp.com
(519) 827-1131